Morphic’s stock falls after new data suggest lower-than-expected efficacy for its ulcerative colitis pill
Morphic Therapeutic saw its shares $MORF slide by 25% Friday to about $38 after data from a small Phase IIa trial showed its inflammatory bowel …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
